Response rates to second-line STS therapies, including pazopanib, are typically <10% with median PFS <5 months, underscoring demand for predictive biomarkers. Transcriptomic profiling of 11 paired pre ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...
Katherine Wilemon, Family Heart Foundation, described the biggest unmet need when it comes to public awareness of Lp(a) and ...
A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease ...
Obesity, MASH, and the Metabolic Dysfunction That Connects Them,' Jaime Almandoz, MD explores the following questions: As an endocrin ...
The Women’s Health Initiative, launched in 1991 across 40 centers with >161,000 participants, materially influenced practice ...
Higher-performing Medicare accountable care organizations are smaller and characterized by real-time information sharing, ...
The FDA approved Moderna’s Biologics License Application (BLA) for its mRNA-based flu vaccine, mRNA-1010 (mFlusiva; Moderna), ...
Disease-modifying antirheumatic drug (DMARD) and tumor necrosis factor (TNF) cycling is a real and well-documented problem in ...
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...
Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results